Topic: Cancer
Conditions
Interventions
1. Paclitaxel, IMP
2. Selumetinib, IMP
Sponsors
University of Liverpool
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically or cytologically confirmed metastatic uveal melanoma 1. Patients must have measurable disease, defined by RECIST 1.1 2. Age at least18 years 3. ECOG performance status 02 4. Life expectancy of greater than 3 months 5. Able to swallow and retain orallyadministered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels 6. All prior treatmentrelated toxicities must be CTCAE v4 grade = 1 (except alopecia) at the time of randomization 7. Laboratory values as listed below (SI units): 7.1. Total bilirubin = 1.5 X institutional upper limit of normal (ULN) 7.2. Aspartate aminotransferase or alanine aminotransferase >2.5 x ULN (or =5 ULN in presence of liver metastases) 7.3. Haemoglobin =9.0 g/dL 7.4. Platelets >100x109/L (100,000 per mm3) 7.5. Absolute neutrophil count >1.5x109/L (1500 per mm3) 7.6. Creatinine = 1.5 mg/dL OR calculated creatinine clearance (CockroftGault formula) =50 mL/min OR 24hour urine creatinine clearance =50 mL/min 8. Female patients of childbearing potential should have a negative pregnancy test
Exclusion criteria
Exclusion criteria: 1. Patients may not have received prior chemotherapy for uveal melanoma. This includes patients who have received isolated hepatic perfusion of chemotherapy. Patients who have received prior immunotherapy or nonchemotherapy locoregional therapy for liver metastases, but who have documented evidence of progression of metastatic disease would however be eligible 2. Patients who have a known or suspected brain metastases or spinal cord compression, unless asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anticonvulsant medications for at least 4 weeks prior to the first dose of study medication 3. Prior exposure to MEK, Ras, or Raf inhibitors or history of hypersensitivity to any excipient agents. 4. History of another malignancy unless diseasefree for 3 years. Patients, who have had a completely resected nonmelanoma skin cancer, are eligible 5. Any permitted previous treatment must have been greater than 21 days prior to study treatment starting and all toxicities from previous treatments should have resolved 6. Symptomatic or untreated leptomeningeal or brain metastases or spinal cord compression. Treated brain metastases must have been stable for at least 1 month 7. Current use of a prohibited medication 8. Cardiac conditions as follows: 8.1. Uncontrolled hypertension (BP =150/95 mmHg despite medical therapy) 8.2. Acute coronary syndrome within 6 months prior to starting treatment 8.3. Baseline Left ventricular ejection fraction (LVEF) below the LLN or 100 bpm on ECG at rest 8.5. Symptomatic heart failure NYHA Class IIIV, prior or current cardiomyopathy, or severe valvular heart disease 8.6. Prior or current cardiomyopathy including but not limited to the following: 8.7. Known hypertrophic cardiomyopathy 8.8. Known arrhythmogenic right ventricular cardiomyopathy 8.9. Previous moderate or severe impairment of left ventricular systolic function (LVEF 450ms or other factors that increase the risk of QT prolongation 9. Ophthalmological conditions as follows (unless in the eye involved by uveal melanoma): 9.1. Intraocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intraocular pressure) 9.2. Current or past history of retinal pigment epithelial detachment (RPED)/central serous retinopathy(CSR) or retinal vein occlusion 10. Uncontrolled intercurrent illness or uncontrolled systemic disease including, but not limited to, ongoing or active infection – including any patient known to have hepatitis B, hepatitis C or human immunodeficiency virus (HIV), symptomatic congestive heart failure, unstable/uncontrolled angina pectoris, uncontrolled cardiac arrhythmia, QTc prolongation, active bleeding diatheses, r
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival (PFS) time.; Timepoint(s): Progression | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. GNAQ/GNA11 mutation status 2. RECIST Response 3. Safety and toxicity | — |
Countries
England, Germany, United Kingdom
Outcome results
None listed